12/23
09:02 am
lixt
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial [Yahoo! Finance]
Low
Report
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial [Yahoo! Finance]
12/23
08:00 am
lixt
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Low
Report
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
12/22
05:36 pm
lixt
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering [Yahoo! Finance]
12/22
04:48 pm
lixt
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
Low
Report
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
12/18
09:00 am
lixt
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
High
Report
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
11/25
08:30 am
lixt
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
High
Report
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
10/29
08:00 am
lixt
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
Low
Report
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
10/16
08:00 am
lixt
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
Medium
Report
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
10/3
03:40 pm
lixt
Lixte Biotechnology (NASDAQ:LIXT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lixte Biotechnology (NASDAQ:LIXT) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.